Evidence map›Paper›PMID 31439831›Full record

Trial reportTranslational psychiatry2019

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis.

Robin Wilson, Matthijs G Bossong, Elizabeth Appiah-Kusi, Natalia Petros, Michael Brammer, Jesus Perez, Paul Allen, Philip McGuire, Sagnik Bhattacharyya

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04831294 (Effects of Cannabidiol), which is not on this map. Cited by 34 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 6 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04831294 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Effects of Cannabidiol (CBD) on the Brain

TypeinterventionalSponsorAuburn UniversityRan2021 to 2023Enrolled15ConditionsCBD, Fear, InhibitionArmsCannabidiol, Placebo
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 6 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Diminished differentiation of rewards in individuals at clinical high-risk for psychosis.European archives of psychiatry and clinical neuroscience · 2024
    Article
  15. Review
  16. The therapeutic potential of purified cannabidiol.Journal of cannabis research · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Robin WilsonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Matthijs G BossongDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Elizabeth Appiah-KusiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Natalia PetrosDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0002-0802-0941
Michael BrammerDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Jesus PerezCAMEO Early Intervention Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
Paul AllenDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Sagnik BhattacharyyaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. sagnik.2.bhattacharyya@kcl.ac.uk.ORCID http://orcid.org/0000-0002-8688-8025
King's College London · GBCambridgeshire and Peterborough NHS Foundation Trust · GBWellcome Centre for Human Neuroimaging · GB

Funding

Department of Health EME/16/126/53Medical Research Council MR/J012149/1RCUK | Medical Research Council (MRC) MR/J012149/1
6 · The paper itself

Abstract

Accumulating evidence points towards the antipsychotic potential of cannabidiol. However, the neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol remain unclear. We investigated this in a double-blind, placebo-controlled, parallel-arm study. We investigated 33 antipsychotic-naïve subjects at clinical high risk for psychosis (CHR) randomised to 600 mg oral cannabidiol or placebo and compared them with 19 healthy controls. We used the monetary incentive delay task while participants underwent fMRI to study reward processing, known to be abnormal in psychosis. Reward and loss anticipation phases were combined to examine a motivational salience condition and compared with neutral condition. We observed abnormal activation in the left insula/parietal operculum in CHR participants given placebo compared to healthy controls associated with premature action initiation. Insular activation correlated with both positive psychotic symptoms and salience perception, as indexed by difference in reaction time between salient and neutral stimuli conditions. CBD attenuated the increased activation in the left insula/parietal operculum and was associated with overall slowing of reaction time, suggesting a possible mechanism for its putative antipsychotic effect by normalising motivational salience and moderating motor response.

Indexed as

AdolescentAdultBrain MappingCannabidiolCerebral CortexDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleMotivationPsychotic DisordersReaction TimeYoung AdultCannabidiol

Identifiers

PMID31439831
PMCPMC6706374
OpenAlexW2968233488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.